GlassScriptPhysician profile
Sarah Alm
NPI 1609344217
$696.46
in general payments reported to CMS, 2019-2025
10 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.71 · 2022: $172 · 2023: $210 · 2024: $174 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $506.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $230.32 | 2022-2024 | Cuvitru |
| Abbvie INC. | $147.57 | 2023-2025 | |
| Insmed, INC. | $76.63 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $54.74 | 2023-2025 | Rebyota |
| Merck Sharp & Dohme LLC | $51.96 | 2022-2023 | Zerbaxa, Dificid, Recarbrio |
| Paratek Pharmaceuticals, INC. | $40.45 | 2024-2025 | Nuzyra |
| Pfizer INC. | $36.49 | 2024 | |
| Viiv Healthcare Company | $23.91 | 2023 | Cabenuva |
| Hospira, INC. | $17.42 | 2024 | |
| Aimmune Therapeutics, INC. | $16.97 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Alm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.